Share this Page:
Pfizer announced this week that the phase III S-TRAC clinical trial of sunitinib versus placebo in patients with renal cell carcinoma (RCC) who are at hight risk of recurrence after surgery has met its primary endpoint of improving disease-free survival (DFS). The S-TRAC trial is the first RCC trial of a tyrosine kinase inhibitor (TKI) to prolong DFS after surgery (in the adjuvant setting). Treatment following surgery (adjuvant therapy) is given to help lower the risk of the cancer coming back in patients with early-stage cancer.
Full results from the S-TRAC trial will be presented at the European Society for Medical Oncology (ESMO) conference in Copenhagen this October 2016.